{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:21:12Z","timestamp":1783592472836,"version":"3.55.0"},"reference-count":73,"publisher":"Bioscientifica","issue":"6","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\u2018Superenhanced\u2019 transcription of oncogenes by aberrant looping of upstream enhancer elements to transcriptional regulatory regions is a mechanism of oncogene overexpression. Non-selective cyclin-dependent kinase inhibitors (CDKi) that target transcriptionally regulatory CDKs, including CDK7, 9, 12 and 13, reduce mRNA levels of super-enhanced oncogenes and have activity against thyroid cancer cells. We hypothesized that more specific inhibitors of CDKs would have differential activities in thyroid cancer cells and may be suitable for further studies. We selected thyroid cancer cell lines with a variety of genetic drivers for initial screening studies with CDK7\/12\/13 (THZ1) and CDK9 (AZD4573) inhibitors. IC50 values ranged from 5 to 100 nM for THZ1 for all cell lines and six of eight cell lines for AZD4573, with inhibition of RNAPII phosphorylation and evidence of reduced cell migration. Four thyroid cancer cell lines with common driver mutations, including 8505C (BRAFV600E), BCPAP (BRAFV600E), TPC1 (RET fusion) and FTC133 (PTEN null), were selected for detailed studies with more specific inhibitors. In these cells, the CDK 12\/13 inhibitor (SR-4835) and AZD4573 were more effective than the specific CDK7 inhibitor YKL-5-124 at reducing cell survival, migration and proliferation, and at inducing apoptosis. Treatment with SR-4835 was the most potent, induced DNA damage and resulted in cyclin K loss. Combined reduction in CDK12\/13 levels with siRNA reduced RNAPII phosphorylation. These data suggest that specific inhibitors of CDK12\/13 may be particularly active in thyroid cancer cell lines; further studies evaluating their efficacy are warranted in thyroid cancer.<\/jats:p>","DOI":"10.1530\/erc-24-0124","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T07:27:16Z","timestamp":1745911636000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":2,"title":["Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells"],"prefix":"10.1530","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4791-9546","authenticated-orcid":true,"given":"Neel","family":"Rajan","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine and Therapeutics, The Ohio State University College of Medicine and Comprehensive Cancer Center 1 , , ,","place":["Columbus, Ohio, USA"]},{"name":"The Ohio State University 2 , , ,","place":["Columbus, Ohio, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilak","family":"Khanal","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Therapeutics, The Ohio State University College of Medicine and Comprehensive Cancer Center 1 , , ,","place":["Columbus, Ohio, USA"]},{"name":"The Ohio State University 2 , , ,","place":["Columbus, Ohio, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Adik","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Therapeutics, The Ohio State University College of Medicine and Comprehensive Cancer Center 1 , , ,","place":["Columbus, Ohio, USA"]},{"name":"The Ohio State University 2 , , ,","place":["Columbus, Ohio, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisley","family":"Valenciaga","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Therapeutics, The Ohio State University College of Medicine and Comprehensive Cancer Center 1 , , ,","place":["Columbus, Ohio, USA"]},{"name":"The Ohio State University 2 , , ,","place":["Columbus, Ohio, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akanksha","family":"Nigam","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Therapeutics, The Ohio State University College of Medicine and Comprehensive Cancer Center 1 , , ,","place":["Columbus, Ohio, USA"]},{"name":"The Ohio State University 2 , , ,","place":["Columbus, Ohio, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandya","family":"Liyanarachchi","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Therapeutics, The Ohio State University College of Medicine and Comprehensive Cancer Center 1 , , ,","place":["Columbus, Ohio, USA"]},{"name":"The Ohio State University 2 , , ,","place":["Columbus, Ohio, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8672-3266","authenticated-orcid":true,"given":"Matthew D","family":"Ringel","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Therapeutics, The Ohio State University College of Medicine and Comprehensive Cancer Center 1 , , ,","place":["Columbus, Ohio, USA"]},{"name":"The Ohio State University 2 , , ,","place":["Columbus, Ohio, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"2026070905480599900_bib1","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.7150\/jca.42849","article-title":"CDK12 promotes papillary thyroid cancer progression through regulating the c-myc\/\u03b2-catenin pathway","volume":"11","author":"Bai","year":"2020","journal-title":"J Cancer"},{"key":"2026070905480599900_bib2","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3390\/biom9100634","article-title":"CDK12 activity-dependent phosphorylation events in human cells","volume":"9","author":"Bartkowiak","year":"2019","journal-title":"Biomolecules"},{"key":"2026070905480599900_bib3","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaa105","article-title":"p21-Activated kinases in thyroid cancer","volume":"161","author":"Bautista","year":"2020","journal-title":"Endocrinology"},{"key":"2026070905480599900_bib4","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1101\/gad.16962311","article-title":"The cyclin K\/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes","volume":"25","author":"Blazek","year":"2011","journal-title":"Genes Dev"},{"key":"2026070905480599900_bib5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid cancer: a review","volume":"331","author":"Boucai","year":"2024","journal-title":"JAMA"},{"key":"2026070905480599900_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13073-014-0123-1","article-title":"From transcriptional regulation to drugging the cancer epigenome","volume":"6","author":"Bradner","year":"2014","journal-title":"Genome Med"},{"key":"2026070905480599900_bib7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","article-title":"Transcriptional addiction in cancer","volume":"168","author":"Bradner","year":"2017","journal-title":"Cell"},{"key":"2026070905480599900_bib8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.molcel.2009.10.019","article-title":"Progression through the RNA polymerase II CTD cycle","volume":"36","author":"Buratowski","year":"2009","journal-title":"Mol Cell"},{"key":"2026070905480599900_bib9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1089\/thy.2018.0550","article-title":"Targeting super-enhancer-driven oncogenic transcription by CDK7 inhibition in anaplastic thyroid carcinoma","volume":"29","author":"Cao","year":"2019","journal-title":"Thyroid"},{"key":"2026070905480599900_bib10","article-title":"Development of an orally bioavailable CDK12\/13 degrader and induction of synthetic lethality with AKT pathway inhibition","volume":"5","author":"Chang","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026070905480599900_bib11","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201847592","article-title":"CDK12 controls G1\/S progression by regulating RNAPII processivity at core DNA replication genes","volume":"20","author":"Chirackal Manavalan","year":"2019","journal-title":"EMBO Rep"},{"key":"2026070905480599900_bib12","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","article-title":"AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells","volume":"26","author":"Cidado","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026070905480599900_bib13","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1089\/thy.2022.0087","article-title":"Blocking CDK7-mediated NOTCH1-cMYC signaling attenuates cancer stem cell activity in anaplastic thyroid cancer","volume":"32","author":"Doolittle","year":"2022","journal-title":"Thyroid"},{"key":"2026070905480599900_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41586-018-0758-y","article-title":"CDK12 regulates DNA repair genes by suppressing intronic polyadenylation","volume":"564","author":"Dubbury","year":"2018","journal-title":"Nature"},{"key":"2026070905480599900_bib15","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1210\/jc.2016-3771","article-title":"Targeting MYC as a therapeutic intervention for anaplastic thyroid cancer","volume":"102","author":"Enomoto","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905480599900_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.44771","article-title":"The complete structure of the human TFIIH core complex","volume":"8","author":"Greber","year":"2019","journal-title":"Elife"},{"key":"2026070905480599900_bib17","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1038\/s41467-019-11536-8","article-title":"The pause-initiation limit restricts transcription activation in human cells","volume":"10","author":"Gressel","year":"2019","journal-title":"Nat Commun"},{"key":"2026070905480599900_bib18","article-title":"CDK9 is up-regulated and associated with prognosis in patients with papillary thyroid carcinoma","volume":"101","author":"Guo","year":"2022","journal-title":"Medicine"},{"key":"2026070905480599900_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1176731","article-title":"Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance","volume":"14","author":"Hamidi","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026070905480599900_bib20","first-page":"372","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed?","volume":"123","author":"Haugen","year":"2016","journal-title":"ACS Journals"},{"key":"2026070905480599900_bib21","doi-asserted-by":"crossref","first-page":"6457","DOI":"10.1038\/s41467-022-34179-8","article-title":"CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma","volume":"13","author":"Houles","year":"2022","journal-title":"Nat Commun"},{"key":"2026070905480599900_bib73","first-page":"65","article-title":"A simple sequentially rejective multiple test procedure","volume":"6","author":"Holm","year":"1979","journal-title":"Scand J Stat"},{"key":"2026070905480599900_bib22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41420-023-01754-x","article-title":"The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma","volume":"9","author":"Houles","year":"2023","journal-title":"Cell Death Discov"},{"key":"2026070905480599900_bib23","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41589-021-00765-y","article-title":"Discovery and resistance mechanism of a selective CDK12 degrader","volume":"17","author":"Jiang","year":"2021","journal-title":"Nat Chem Biol"},{"key":"2026070905480599900_bib24","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1016\/j.molcel.2024.10.045","article-title":"The PNUTS phosphatase complex controls transcription pause release","volume":"84","author":"Kelley","year":"2024","journal-title":"Mol Cell"},{"key":"2026070905480599900_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41589-023-01409-z","article-title":"Design principles for cyclin K molecular glue degraders","volume":"20","author":"Kozicka","year":"2024","journal-title":"Nat Chem Biol"},{"key":"2026070905480599900_bib26","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/s41467-019-09703-y","article-title":"CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation","volume":"10","author":"Krajewska","year":"2019","journal-title":"Nat Commun"},{"key":"2026070905480599900_bib27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cub.2008.11.052","article-title":"Eukaryotic trancription initiation","volume":"19","author":"Krishnamurthy","year":"2009","journal-title":"Curr Biol"},{"key":"2026070905480599900_bib71","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-18-2953","article-title":"Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies","volume":"25","author":"Landa","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026070905480599900_bib28","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/nsmb.2399","article-title":"Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II","volume":"19","author":"Larochelle","year":"2012","journal-title":"Nat Struct Mol Biol"},{"key":"2026070905480599900_bib29","first-page":"27","article-title":"Targeting transcriptional regulators for treatment of anaplastic thyroid cancer","volume":"7","author":"Lee","year":"2021","journal-title":"J Cancer Metastasis Treat"},{"key":"2026070905480599900_bib30","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2020.11.045","article-title":"CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K\/AKT","volume":"145","author":"Li","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026070905480599900_bib31","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/carcin\/bgae051","article-title":"CDK12 is a promising therapeutic target for the transcription cycle and DNA damage response in metastatic osteosarcoma","volume":"45","author":"Li","year":"2024","journal-title":"Carcinogenesis"},{"key":"2026070905480599900_bib32","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.7150\/thno.46137","article-title":"CDK12 and PAK2 as novel therapeutic targets for human gastric cancer","volume":"10","author":"Liu","year":"2020","journal-title":"Theranostics"},{"key":"2026070905480599900_bib33","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40618-018-0947-4","article-title":"The efficacy of HRAS and CDK4\/6 inhibitors in anaplastic thyroid cancer cell lines","volume":"42","author":"Lopes-Ventura","year":"2019","journal-title":"J Endocrinol Investig"},{"key":"2026070905480599900_bib34","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Loven","year":"2013","journal-title":"Cell"},{"key":"2026070905480599900_bib35","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1021\/acs.jmedchem.4c01616","article-title":"Design, synthesis, and biological evaluation of novel orally available covalent CDK12\/13 dual inhibitors for the treatment of tumors","volume":"68","author":"Lu","year":"2025","journal-title":"J Med Chem"},{"key":"2026070905480599900_bib36","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1677\/ERC-10-0168","article-title":"Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion","volume":"17","author":"Mccarty","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"2026070905480599900_bib37","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2174\/1568009623666230320144713","article-title":"An overview of CDK enzyme inhibitors in cancer therapy","volume":"23","author":"Mounika","year":"2023","journal-title":"Curr Cancer Drug Targets"},{"key":"2026070905480599900_bib38","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ijc.33690","article-title":"Thyroid cancer, recent advances in diagnosis and therapy","volume":"149","author":"Nabhan","year":"2021","journal-title":"Int J Cancer"},{"key":"2026070905480599900_bib39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2017.05.017","article-title":"Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway","volume":"402","author":"Nakamura","year":"2017","journal-title":"Cancer Lett"},{"key":"2026070905480599900_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114012","article-title":"Noncovalent CDK12\/13 dual inhibitors-based PROTACs degrade CDK12-cyclin K complex and induce synthetic lethality with PARP inhibitor","volume":"228","author":"Niu","year":"2022","journal-title":"Eur J Med Chem"},{"key":"2026070905480599900_bib41","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.chembiol.2019.02.012","article-title":"Development of a selective CDK7 covalent inhibitor reveals predominant cell-cycle phenotype","volume":"26","author":"Olson","year":"2019","journal-title":"Cell Chem Biol"},{"key":"2026070905480599900_bib42","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1089\/thy.2019.0415","article-title":"Thyroid cancer incidence trends in the United States: association with changes in professional guidelines recommendations","volume":"33","author":"Pereira","year":"2020","journal-title":"Thyroid"},{"key":"2026070905480599900_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239315","article-title":"Flavopiridol causes cell cycle inhibition and demonstrates anti-cancer activity in anaplastic thyroid cancer models","volume":"15","author":"Pinto","year":"2020","journal-title":"PLoS One"},{"key":"2026070905480599900_bib44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ng.3167","article-title":"What are super-enhancers?","volume":"47","author":"Pott","year":"2014","journal-title":"Nat Genet"},{"key":"2026070905480599900_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf8698","article-title":"CDK12 and Integrator-PP2A complex modulates LEO1 phosphorylation for processive transcription elongation","volume":"9","author":"Qiu","year":"2023","journal-title":"Sci Adv"},{"key":"2026070905480599900_bib46","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ccell.2019.09.004","article-title":"Therapeutic targeting of CDK12\/CDK13 in triple-negative breast cancer","volume":"36","author":"Quereda","year":"2019","journal-title":"Cancer Cell"},{"key":"2026070905480599900_bib47","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1210\/clinem\/dgaa687","article-title":"New horizons: emerging therapies and targets in thyroid cancer","volume":"106","author":"Ringel","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070905480599900_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146021","article-title":"Dose-response analysis using R","volume":"10","author":"Ritz","year":"2015","journal-title":"PLoS One"},{"key":"2026070905480599900_bib48","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13059-024-03278-8","article-title":"Genome-wide identification of replication fork stalling\/pausing sites and the interplay between RNA Pol II transcription and DNA replication progression","volume":"25","author":"Rojas","year":"2024","journal-title":"Genome Biol"},{"key":"2026070905480599900_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2024.102485","article-title":"Role of specific CDKs in regulating DNA damage repair responses and replication stress","volume":"79","author":"Roy","year":"2024","journal-title":"Curr Opin Pharmacol"},{"key":"2026070905480599900_bib50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13000-017-0661-0","article-title":"cMYC expression in thyroid follicular cell-derived carcinomas: a role in thyroid tumorigenesis","volume":"12","author":"Sakr","year":"2017","journal-title":"Diagn Pathol"},{"key":"2026070905480599900_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105501","article-title":"The reversible inhibitor SR-4835 binds Cdk12\/cyclin K in a noncanonical G-loop conformation","volume":"300","author":"Schmitz","year":"2024","journal-title":"J Biol Chem"},{"key":"2026070905480599900_bib52","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026070905480599900_bib53","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1073\/pnas.1717920115","article-title":"Live-cell analysis of endogenous GFP-RPB1 uncovers rapid turnover of initiating and promoter-paused RNA polymerase II","volume":"115","author":"Steurer","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070905480599900_bib54","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1038\/s41467-022-31329-w","article-title":"DNA damage-induced transcription stress triggers the genome-wide degradation of promoter-bound pol II","volume":"13","author":"Steurer","year":"2022","journal-title":"Nat Commun"},{"key":"2026070905480599900_bib55","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1158\/1535-7163.MCT-21-0891","article-title":"CDK7 inhibition synergizes with topoisomerase I inhibition in small cell lung cancer cells by inducing ubiquitin-mediated proteolysis of RNA polymerase II","volume":"21","author":"Sun","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2026070905480599900_bib56","article-title":"CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13","volume":"5","author":"Tien","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026070905480599900_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.122225","article-title":"Transcriptional targeting of oncogene addiction in medullary thyroid cancer","volume":"3","author":"Valenciaga","year":"2018","journal-title":"JCI Insight"},{"key":"2026070905480599900_bib58","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1073\/pnas.0610733104","article-title":"Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion","volume":"104","author":"Vasko","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070905480599900_bib59","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1530\/ERC-19-0011","article-title":"PI3K\/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer","volume":"26","author":"Wong","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"2026070905480599900_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188842","article-title":"Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy","volume":"1878","author":"Wu","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2026070905480599900_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107097","article-title":"CDK12 inhibition upregulates ATG7 triggering autophagy via AKT\/FOXO3 pathway and enhances anti-PD-1 efficacy in colorectal cancer","volume":"201","author":"Wu","year":"2024","journal-title":"Pharmacol Res"},{"key":"2026070905480599900_bib62","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.3390\/cells12162044","article-title":"Coming of age: targeting cyclin K in cancers","volume":"12","author":"Xiao","year":"2023","journal-title":"Cells"},{"key":"2026070905480599900_bib63","doi-asserted-by":"crossref","first-page":"11066","DOI":"10.1021\/acs.jmedchem.2c00384","article-title":"Discovery of a highly potent and selective dual PROTAC degrader of CDK12 and CDK13","volume":"65","author":"Yang","year":"2022","journal-title":"J Med Chem"},{"key":"2026070905480599900_bib64","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nchembio.2166","article-title":"Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors","volume":"12","author":"Zhang","year":"2016","journal-title":"Nat Chem Biol"},{"key":"2026070905480599900_bib65","first-page":"1913","article-title":"CDK inhibitors in cancer therapy, an overview of recent development","volume":"11","author":"Zhang","year":"2021","journal-title":"Am J Cancer Res"},{"key":"2026070905480599900_bib66","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1021\/acs.jmedchem.4c00312","article-title":"Recent discovery and development of inhibitors that target CDK9 and their therapeutic indications","volume":"67","author":"Zhang","year":"2024","journal-title":"J Med Chem"},{"key":"2026070905480599900_bib67","doi-asserted-by":"crossref","first-page":"369","DOI":"10.4155\/fmc-2023-0259","article-title":"Molecules inducing specific cyclin-dependent kinase degradation and their possible use in cancer therapy","volume":"16","author":"Zheng","year":"2024","journal-title":"Future Med Chem"},{"key":"2026070905480599900_bib68","doi-asserted-by":"crossref","first-page":"18247","DOI":"10.1021\/acs.jmedchem.4c01596","article-title":"Discovery of ZLC491 as a potent, selective, and orally bioavailable CDK12\/13 PROTAC degrader","volume":"67","author":"Zhou","year":"2024","journal-title":"J Med Chem"},{"key":"2026070905480599900_bib69","doi-asserted-by":"crossref","first-page":"35408","DOI":"10.18632\/oncotarget.26253","article-title":"Synergistic effects of BET and MEK inhibitors promote regression of anaplastic thyroid tumors","volume":"9","author":"Zhu","year":"2018","journal-title":"Oncotarget"},{"key":"2026070905480599900_bib70","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1530\/ERC-19-0107","article-title":"Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer","volume":"26","author":"Zhu","year":"2019","journal-title":"Endocr Relat Cancer"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/6\/ERC-24-0124.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/6\/ERC-24-0124.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0124\/247075\/erc-24-0124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0124\/247075\/erc-24-0124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:48:25Z","timestamp":1783590505000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/6\/e240124\/26078\/Differential-activity-of-specific-inhibitors-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-24-0124","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"article-number":"e240124"}}